April 28, 2022
10 min watch
Save
Video: DIAMOND study probes patiromer’s use in reducing hyperkalemia
In this video, Uri Elkayam, MD, gave Healio an in-depth look at the DIAMOND study presented at the American College of Cardiology Scientific Session.
Elkayam, professor of medicine at the University of Southern California Keck School of Medicine in Los Angeles, spoke extensively on all facets of the study, which showed that patiromer (Veltassa, Vifor Pharma) was effective at reducing the risk for hyperkalemia in patients with HF with reduced ejection fraction.
Elkayam, who also presented the implications of the study, said in some patients where hyperkalemia is a risk, the use of potassium binders should improve patient outcomes.
Reference:
- Szecsödy P. Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND). Presented at: American College of Cardiology Scientific Session; April 2-4, 2022; Washington, D.C.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Elkayam reports no relevant financial disclosures.
Read more about